WuXi Biologics (Cayman) Inc. (2269.HK)

HKD 24.1

(5.7%)

Total Liabilities Summary of WuXi Biologics (Cayman) Inc.

WuXi Biologics (Cayman) Inc.'s latest annual total liabilities in 2023 was 12.55 Billion CNY , down -5.94% from previous year.
WuXi Biologics (Cayman) Inc.'s latest quarterly total liabilities in 2024 Q2 was 11.46 Billion CNY , down 0.0% from previous quarter.
WuXi Biologics (Cayman) Inc. reported annual total liabilities of 13.35 Billion CNY in 2022, up 17.88% from previous year.
WuXi Biologics (Cayman) Inc. reported annual total liabilities of 11.32 Billion CNY in 2021, up 40.45% from previous year.
WuXi Biologics (Cayman) Inc. reported quarterly total liabilities of 11.46 Billion CNY for 2024 Q1, down -8.7% from previous quarter.
WuXi Biologics (Cayman) Inc. reported quarterly total liabilities of 12.55 Billion CNY for 2023 FY, down -5.94% from previous quarter.

Annual Total Liabilities Chart of WuXi Biologics (Cayman) Inc. (2023 - 2014)

Historical Annual Total Liabilities of WuXi Biologics (Cayman) Inc. (2023 - 2014)

Year	Total Liabilities	Total Liabilities Growth
2023	12.55 Billion CNY	-5.94%
2022	13.35 Billion CNY	17.88%
2021	11.32 Billion CNY	40.45%
2020	8.06 Billion CNY	71.35%
2019	4.7 Billion CNY	236.41%
2018	1.39 Billion CNY	69.65%
2017	824.6 Million CNY	-51.91%
2016	1.71 Billion CNY	41.61%
2015	1.21 Billion CNY	357.15%
2014	264.84 Million CNY	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	11.46 Billion CNY	0.0%
2024 Q1	11.46 Billion CNY	-8.7%
2023 FY	12.55 Billion CNY	-5.94%
2023 Q3	12.55 Billion CNY	-4.12%
2023 Q4	12.55 Billion CNY	0.0%
2023 Q2	13.09 Billion CNY	0.0%
2023 Q1	13.09 Billion CNY	-1.91%
2022 Q3	13.35 Billion CNY	11.33%
2022 Q1	11.99 Billion CNY	5.88%
2022 FY	13.35 Billion CNY	17.88%
2022 Q4	13.35 Billion CNY	0.0%
2022 Q2	11.99 Billion CNY	0.0%
2021 Q3	11.32 Billion CNY	13.3%
2021 FY	11.32 Billion CNY	40.45%
2021 Q1	9.99 Billion CNY	23.97%
2021 Q4	11.32 Billion CNY	0.0%
2021 Q2	9.99 Billion CNY	0.0%
2020 Q4	8.06 Billion CNY	0.0%
2020 FY	8.06 Billion CNY	71.35%
2020 Q1	6.94 Billion CNY	47.58%
2020 Q2	6.94 Billion CNY	0.0%
2020 Q3	8.06 Billion CNY	16.11%
2019 FY	4.7 Billion CNY	236.41%
2019 Q4	4.7 Billion CNY	0.0%
2019 Q3	4.7 Billion CNY	182.2%
2019 Q2	1.66 Billion CNY	0.0%
2019 Q1	1.66 Billion CNY	19.21%
2018 Q1	990.17 Million CNY	20.08%
2018 Q4	1.39 Billion CNY	6.08%
2018 Q3	1.31 Billion CNY	24.5%
2018 Q2	1.05 Billion CNY	6.97%
2018 FY	1.39 Billion CNY	69.65%
2017 Q1	1.8 Billion CNY	5.55%
2017 FY	824.6 Million CNY	-51.91%
2017 Q4	824.6 Million CNY	3.32%
2017 Q3	798.07 Million CNY	-55.9%
2017 Q2	1.8 Billion CNY	0.0%
2016 Q1	- CNY	-100.0%
2016 Q4	1.71 Billion CNY	0.0%
2016 FY	1.71 Billion CNY	41.61%
2015 Q4	1.2 Billion CNY	0.0%
2015 FY	1.21 Billion CNY	357.15%
2014 FY	264.84 Million CNY	0.0%

Peer Total Liabilities Comparison of WuXi Biologics (Cayman) Inc.

Name	Total Liabilities	Total Liabilities Difference
Uni-Bio Science Group Limited	152.81 Million HKD	-8117.516%
CK Life Sciences Int'l., (Holdings) Inc.	7.05 Billion HKD	-77.92%